|
US2021020317A1
|
|
Sensitive drug distribution systems and methods
|
|
AU2019252790A1
|
|
Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion
|
|
US2015202588A1
|
|
Devices and methods for facilitating and controlling use of a medication
|
|
US2014348917A1
|
|
Immediate release formulations and dosage forms of gamma-hydroxybutyrate
|
|
US2014296830A1
|
|
Methods of administering drugs in an implantable multi-chamber pump
|
|
US8591922B1
|
|
Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
|
|
CN102917697A
|
|
Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
|
|
WO2011139271A1
|
|
Immediate release formulations and dosage forms of gamma-hydroxybutyrate
|
|
US2010138237A1
|
|
Sensitive drug distribution system and method
|
|
CA2740146A1
|
|
Immediate release dosage forms of sodium oxybate
|
|
TW200824693A
|
|
Pharmaceutical compositions of clonazepam and methods of use thereof
|
|
TW200815045A
|
|
Pharmaceutical compositions of ropinirole and methods of use thereof
|
|
CA2597910A1
|
|
Dosage form and method for sustained release of a substituted pyrazine compound
|
